Condition: Healthy · Rheumatoid Arthritis · Sponsor: ILAb Co., Ltd.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending oral doses of IA-14069 in healthy subjects and in patients with RA on stable dosese of MTX, with preliminary assessment of efficacy in RA patients.
This description comes directly from the study's public registry record.
Tae-Hwe Heo, Ph.D. · +82-10-4596-2447 · taehwe.heo@ilab.co.kr
Youjin Jang, M.S. · +82-10-4300-0206 · youjin.jang@ilab.co.kr
Always discuss trial participation with your own doctor first.
| ICON plc. | Lenexa, Kansas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05533372